Stewart Jeffrey Ryan
Form 3
December 12, 2018

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Â Stewart Jeffrey Ryan
(Last) (First) (Middle)

1 NORTH WAUKEGAN ROAD
(Street)

NORTH
CHICAGO,Â ILÂ 60064
(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/10/2018

3. Issuer Name **and** Ticker or Trading Symbol
AbbVie Inc. [ABBV]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__X__ Officer (give title below)
_____ Other (specify below)
SVP, US Commercial Operations

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, $0.01 par value	29,478	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of			

				Shares		(I) (Instr. 5)	
Option (right to buy)	Â (1)	02/19/2024	Common stock	25,290	$ 51.42	D	Â
Option (right to buy)	Â (2)	02/18/2025	Common stock	27,690	$ 58.88	D	Â
Option (right to buy)	Â (3)	02/17/2026	Common stock	21,810	$ 54.86	D	Â
Option (right to buy)	Â (4)	02/15/2027	Common stock	26,110	$ 61.36	D	Â
Option (right to buy)	Â (5)	02/14/2028	Common stock	16,070	$ 114.36	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Stewart Jeffrey Ryan 1 NORTH WAUKEGAN ROAD NORTH CHICAGO,Â ILÂ 60064	Â	Â	Â SVP, US Commercial Operations	Â

Signatures

Steven L. Scrogham, attorney-in-fact for Jeffrey R. Stewart	12/12/2018
**Signature of Reporting Person	Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 8,430 shares on 2/20/2015, as to 8,430 shares on 2/20/2016 and as to 8,430 shares on 2/20/2017.

(2) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,230 shares on 2/19/2016, as to 9,230 shares on 2/19/2017 and as to 9,230 shares on 2/19/2018.

(3) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,270 shares on 2/18/2017 and as to 7,270 shares on 2/18/2018, and becomes exercisable as to 7,270 shares on 2/18/2019.

(4) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 8,704 shares on 2/16/2018, and becomes exercisable as to 8,703 shares on 2/16/2019 and as to 8,703 shares on 2/16/2020.

(5) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable as to 5,357 shares on 2/15/2019, as to 5,356 shares on 2/15/2020 and as to 5,357 shares on 2/15/2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.